Other

Equity Securities, FV-NI, Equity Securities Without Readily Determinable Fair Value, And Equity Method Investments

Medtronic Equity Securities, FV-NI, Equity Securities Without Readily Determinable Fair Value, And Equity Method Investments increased by 17.9% to $1.00B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 18.5%, from $1.23B to $1.00B.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ2 2024
Last reportedQ1 2026
Metric ID: other_equity_securities_fvni_equity_securities_without_r_1dc670

Historical Data

6 periods
 Q2 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$1.28B$1.23B$951.00M$850.00M$851.00M$1.00B
QoQ Change—-4.1%-22.7%-10.6%+0.1%+17.9%
YoY Change——-25.8%——-18.5%
Range$850.00M – $1.28B
CAGR-17.8%
Avg YoY Growth-22.1%
Median YoY Growth-22.1%
Current Streak2 quarters growth

Frequently Asked Questions

What is Medtronic's equity securities, fv-ni, equity securities without readily determinable fair value, and equity method investments?
Medtronic (MDT) reported equity securities, fv-ni, equity securities without readily determinable fair value, and equity method investments of $1.00B in Q1 2026.
How has Medtronic's equity securities, fv-ni, equity securities without readily determinable fair value, and equity method investments changed year-over-year?
Medtronic's equity securities, fv-ni, equity securities without readily determinable fair value, and equity method investments decreased by 18.5% year-over-year, from $1.23B to $1.00B.